A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials.
Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.

Includes supplementary material: sn.pub/extras

Zusammenfassung
"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field."
-Intensive Care Medicine

Inhalt
1 Thrombosis in Acute Coronary Syndromes and Coronary Interventions.- 2 Platelet Adhesion.- 3 Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis.- 4 Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Abciximab, Tirofiban, and Eptifibatide.- 5 Abciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT Trials.- 6 Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials.- 7 Tirofiban in Interventional Cardiology: The RESTORE and TARGET Trials.- 8 Overview of the Glycoprotein IIb/Illa Interventional Trials.- 9 The Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE Study.- 10 Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV.- 11 Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy.- 12 Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary Interventions.- 13 Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to Fibrinolysis.- 14 Economics of Glycoprotein IIb/IIIa Inhibition.- 15 Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents.- 16 Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors.- 17 Oral Agents.- 18 Platelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the Platelet.- 19 Cerebrovascular Interventions.- 20 Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors.- 21 Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future.